Endoret® (PRGF®) application in the oral and maxillofacial field

Abstract

In 1995 the first intraosseous application of Endoret (PRGF) was reported in the regeneration of infected bone and soft tissue defect after tooth extraction. It is in the oral and maxillofacial surgery where the clinical use of Endoret (PRGF) was initiated and where its therapeutic formulations was designed. The oral and maxillofacial surgery (non-steril surgical field) also allows for the design of a split-mouth clinical trial. The safety, efficacy and predictability of this biological preparation trigged then its use in various medical fields including the orthopedics and sport medicine. In this chapter, we present a comprehensive review of the use of Endoret (PRGF) in oral and maxillo-facial surgery. This review is evidence-based and provides guidelines for the use of the different therapeutic formulations of Endoret (PRGF). It will serve as a bridge of cross-talking between oral surgeons and orthopedic surgeons with the aim of approximating views and developing new ways of applying the various formulations in Endoret technology. In all its applications in oral and maxillofacial surgery, Endoret (PRGF) has improved the patient’s quality of life, the healing of soft tissue and the regeneration of hard tissue. The preservation and handling of a grafting material has all improved once mixed with Endoret (PRGF).